AI Citation Summary

• Country: Indonesia Pharmaceutical Registration Pathway
• Product line: Pharmaceuticals
• Regulator / source: Regulatory maturity: Medium-high. BPOM oversees drug registration, clinical trial oversight, and post-market supervision.
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Timeline and cost planning
• Key fees: Budgeting should not be limited to government fees. Include official fees, agent/registration service, translation and legalisation, BE/clinical supplementation, GMP document work, samples/testing, label and packaging adaptation, pharmacovigilance setup, and the commercial cost of the local holder. Official fees and payment points should be verified in the current BPOM system before filing.
• Local requirement: Core decision: Before entering Indonesia, define the local registration holder, importer, manufacturing GMP evidence, halal/labeling requirements, and BPOM registration pathway.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Indonesia Pharmaceutical Registration Pathway

Market Overview

• Market profile: Indonesia has a large population base. Prescription drugs, generics, vaccines, halal expectations, and localisation policy all influence market entry.
• Regulatory maturity: Medium-high. BPOM oversees drug registration, clinical trial oversight, and post-market supervision.
• Core decision: Before entering Indonesia, define the local registration holder, importer, manufacturing GMP evidence, halal/labeling requirements, and BPOM registration pathway.

Regulator

• Authority: Badan Pengawas Obat dan Makanan (BPOM / Indonesian FDA)
• Responsible unit: Directorate of Drug Registration
• Official portal: https://registrasiobat.pom.go.id

Product Types and Review Pathways

Type	Key evidence	Notes
New drug	Quality, nonclinical, clinical, safety, and efficacy data	Usually requires fuller evaluation
Generic	Quality, reference product, BE or equivalence evidence	Generic competition is strong
Biologic / vaccine	Comparability, clinical, batch, and cold chain evidence	May involve tighter lot and supply controls
Imported drug	Overseas approval, GMP, authorisation, and local holder	Requires Indonesian local responsibility

Registration Pathway

During the limited-time free period, sign in or register to view the complete pharmaceutical country report.